Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Saniona completed toxicology and CMC work for SAN2465, clearing the package needed to support an IND filing. IND submission to the FDA is targeted by end-October 2026, setting up first-in-human dosing plans. Planned Phase 1 trial targets safety, tolerability, pharmacokinetics in healthy volunteers, with biomarker reado
Saniona completed toxicology and CMC work for SAN2465 and expects to submit an IND to the FDA by the end of October 2026. A Phase 1 study in healthy volunteers is planned.Material DetailsContext by AI AnalystThis is an early clinical-stage milestone advancing a preclinical asset toward first-in-hum…